Angiogenesis in cancer and other diseases

By Peter Carmeliet, Rakesh K. Jain. Nature, 2000

9,280 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/0caa1375299f3fe4f20e3fb1646518c8cf7c845e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (2001, background): “What mechanisms are responsible for this normalization? How can we exploit them? This knowledge will affect the treatment not only of cancer but also of other diseases characterized by abnormal vasculature—such as hemangiomas, arteriovenous malformations, diabetic retinopathy and macular degeneratio”
Diabetes and Wound Angiogenesis (2017, background): “disease states, angiogenesis can be persistent, disorganized, and never reaches attenuation [31,32].”
The microenvironment of the tumour–host interface (2001, background): “In response to trophic signals, vascular cells, wounded epithelial sheets or neurites will migrate, penetrate tissue barriers and establish appropriate new anastomose”
Breast MRI: State of the Art. (2019, background): “The underlying principle is that neoangiogenesis leads to formation of leaky vessels that allow for faster extravasation of contrast agents (7), thus leading to rapid local enhancement.”
The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease (2005, background): “VEGF-A-driven angiogenesis has a major role in the pathogenesis of diverse human diseases, including cancer, eye disorders and rheumatoid arthritis [44].”
Functional classification of interferon‐stimulated genes identified using microarrays (2001, background): “Most of these growth factors are mitogenic and have been implicated in the control of angiogenesis and cancer [59–62], raising the interesting possibility that IFNs may influence angiogenesis.”
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors (2005, background): “In contrast, vessel formation in tumors appears much less programmed and is improvised from a limited array of stimulatory factors (Carmeliet and Jain, 2000; McDonald and Choyke, 2003).”
Therapeutic targeting of the tumor microenvironment. (2005, neutral): “Another barrier results from the chaot ic nature of the tumor vasculature, as tumor vessels are dilated, leaky, and tortuous ( Carmeliet and Jain, 2000 ), which further contributes to decreased drug delivery.”
Revisiting the hallmarks of cancer. (2017, neutral): “The sprouting tumor vasculature differs from normal one [77, 88].”
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. (2012, background): “One of the main factors involved in the activation of angiogenesis is the vascular endothelial growth factor (VEGF), which operates mainly through three tyrosine kinase membrane receptors (VEGFR 1–3).(84) The tumor neovasculature is characterized by vessel excessive branching, architectural distorti”
A review of imaging techniques for systems biology (2008, background): “The uptake of tracer into tissues is proportional to delivery, and so is a measure of perfusion [87].”